TP53 and cancer: We successfully showed reactivation of wild-type p53 and reduced cell proliferation and migration, following transfection of these mutant-specific siRNAs in genetically engineered p53 heterozygous cancer cell lines (HCT116+/R248W, SW48+/R273H) (unpublished).